Zhongyu M. Yuan

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Author Correction: Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.

Author Correction: Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.

Journal: Nature communications

Published: February 20, 2026

Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study.

Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: December 13, 2025

Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors.

Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors.

Journal: Therapeutic advances in medical oncology

Published: September 21, 2025

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort.

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort.

Journal: Cancer medicine

Published: August 30, 2025

Corrigendum to "Doxorubicin delivered by redox-responsive Hyaluronic Acid-Ibuprofen prodrug micelles for treatment of metastatic breast cancer" [Carbohydrate Polymers 245 (2020) 116527].

Corrigendum to "Doxorubicin delivered by redox-responsive Hyaluronic Acid-Ibuprofen prodrug micelles for treatment of metastatic breast cancer" [Carbohydrate Polymers 245 (2020) 116527].

Journal: Carbohydrate polymers

Published: July 30, 2025

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Journal: NPJ breast cancer

Published: July 21, 2025

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy.

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy.

Journal: The oncologist

Published: July 14, 2025

Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study.

Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study.

Journal: Cancer science

Published: May 14, 2025

HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy.

HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy.

Journal: Frontiers in immunology

Published: May 06, 2025

Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors.

Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors.

Journal: Journal of breast cancer

Published: September 26, 2024

Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.

Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.

Journal: MedComm

Published: September 08, 2024

Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer.

Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: June 22, 2024

Showing 1-12 of 69

Last Updated: 09/26/2026